Release of Nociceptin From Granulocytes in Sepsis

Completed

Conditions: Septic Shock
Severe Sepsis
Sepsis Syndrome
Sepsis

Interventions: Diagnostic Test: Septic

Registration Number: NCT03037281

Lead Sponsor: University of Leicester

Brief Summary: Nociceptin is a protein found in the body, with a number of functions in the central nervous system, blood vessels and the gut. There is evidence that it may have a role in controlling the immune response to infection, and may act as a link between the brain and immune system.

In infection, or after surgery, there is an increase in nociceptin, and subjects greater elevations of nociceptin have a poorer outcome. There is evidence that cells of the immune system may produce nociceptin, although it is not yet known which cells are capable of producing it, and what "switches on" production.

This study aims to determine

1. Which cells of the immune system can produce nociceptin

2. If there is a difference in the ability to produce nociceptin between healthy volunteers and patients with severe infections

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 14

Inclusion Criteria

For septic patients;
1. Participant is willing and able to give informed consent for participation in the study, or if lacking capacity, a next of kin or advocate is willing and able to give assent for participation in the study. Must be able to read and understand English.
2. Male or Female, aged 18 years or above.
3. Diagnosed with sepsis and admitted to the intensive care unit.
4. Able (in the Investigators opinion) and willing to comply with all study requirements.
5. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Healthy Volunteers;

Participant is willing and able to give informed consent for participation in the study. Must be able to read and understand English.
Male or Female, aged 18 years or above and be
In good health.
Have had no course of medication, whether prescribed or over-the-counter, in the four weeks before first study dose and no individual doses in the final two weeks other than mild analgesia, vitamins and mineral supplements or, for females, oral contraceptives
Able (in the Investigators opinion) and willing to comply with all study requirements.
Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion Criteria

1. Conditions which may make phlebotomy hazardous to the participant (such as significant bleeding disorders or anaemia, or allergy), or to the investigator (blood viral infection).
2. Any significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
3. Participants who have participated in another research study involving an investigational product in the past 12 weeks.

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Septic	Septic	Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse \>90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
Healthy volunteers	Septic	Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.

Primary Outcome Measures

Name	Time	Method
Proportion of Responsive Biosensor Cells Responding to Granulocyte Addition in the Presence and Absence of NOP Antagonist	Day 1	Measure of N/OFQ presence in granulocytes and associated supernatant

Secondary Outcome Measures

Name	Time	Method
Acute Physiology and Chronic Health Evaluation (APACHE-2) Score	Day 1	The Acute Physiology and Chronic Health Evaluation (APACHE-2) score for the patient. APACHE 2 is an international standard,12 variable score from 0-71 reflecting disease severity in the critically unwell during the first 24 hours of illness. The score is a combined measure of illness severity (acute physiology), and background chronic health factors. Increased score represents increased predicted mortality. Variables recorded include AaDO2 or PaO2 (depending on FiO2), temperature, mean arterial pressure, blood pH, heart rate, respiratory rate, serum sodium, serum potassium, creatinine, hematocrit, white blood cell count, Glasgow Coma Scale Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985). "APACHE II: a severity of disease classification system". Critical Care Medicine. 13 (10): 818-29
Sequential Organ Failure Assessment (SOFA) Score	Day 1	The Sequential Organ Failure Assessment (SOFA) score for the patient, a score predictive of mortality in sepsis for intensive care patients based on respiratory, cardiovascular, hepatic, coagulation, renal and neurological function (each scored 0-4, with a maximum overall score of 24). The worst (most deranged) physiological values for the first 24 hours are used. A higher score predicts increased mortality. The mortality breakdown for each sofa score range is - SOFA 0-6 (\<10% mortality), 7-9 (15-20%), 10-12 (40-50%), 13-14 (50 - 60%), 15 (\> 80%), 16 to 24 (\> 90%)
Granulocyte Count	Day 1	Count of the number of neutrophils in the original sample
Mortality In-hospital, at 30 Days	30 days	All cause mortality at 30 days
Time to ICU Discharge (or Death if on ICU)	Time to ICU discharge (or death if on ICU)
Time to Death or Discharge	Number of days between admission and death or discharge from hospital	Time to death or discharge (days)

Trial Locations

Locations (2): Leicester Royal Infirmary
🇬🇧
Leicester, Leicestershire, United Kingdom
University of Leicester
🇬🇧
Leicester, Leicestershire, United Kingdom